The metabolic activity of the CLL cells treated with 1 nM venetoclax alone was 48%, which was significantly lower than for the cells co-treated with IFNγ (110%), PMA/ionomycin (78%), and sCD40L (62%). Here, IFNG is linked to B-cell chronic lymphocytic leukemia.